Menu
Search
|

Menu

Close
X

Kindred Biosciences Inc KIN.OQ (NASDAQ Stock Exchange Capital Market)

12.85 USD
+0.00 (+0.00%)
As of 1:30 AM IST
chart
Previous Close 12.85
Open 12.90
Volume 24,233
3m Avg Volume 33,064
Today’s High 12.95
Today’s Low 12.82
52 Week High 12.95
52 Week Low 6.60
Shares Outstanding (mil) 27.84
Market Capitalization (mil) 225.49
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.356
FY17
-1.227
FY16
-1.132
FY15
-1.372
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
2.64
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-34.47
14.61
Return on Equity (TTM)
vs sector
-34.50
16.34

EXECUTIVE LEADERSHIP

Wendy Wee
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Denise Bevers
Chief Operating Officer, Secretary, Since 2013
Salary: $294,250.00
Bonus: $92,690.00
Hangjun Zhan
Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Joseph McCracken
Director, Since 2018
Salary: --
Bonus: --
Ernest Mario
Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1555 Bayshore Hwy Ste 200
BURLINGAME   CA   94010-1617

Phone: +1650.7017901

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

SPONSORED STORIES